A Long Term Safety Study of BCX7353 in Hereditary Angioedema
-
- STATUS
- Recruiting
-
- End date
- Feb 15, 2024
-
- participants needed
- 475
-
- sponsor
- BioCryst Pharmaceuticals
Updated on 23 December 2020
Clinical Trials Coordinator
Primary Contact
Study Center (2.2 mi away) Contact
+92 other locationangioedema
Summary
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Details
| Treatment | BCX7353 |
|---|---|
| Clinical Study Identifier | NCT03472040 |
| Sponsor | BioCryst Pharmaceuticals |
| Last Modified on | 23 December 2020 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer